Sanofi is undergoing a transition in its research priorities with the appointment of a new CEO. This change may signal a strategic shift in the company's approach to innovation.
Among the highlighted areas of interest is a gene therapy aimed at addressing deafness, which could represent a significant advancement in treatment options.
Additionally, the biotech landscape is closely watching developments related to Erasca, indicating that Sanofi's new leadership may be recalibrating its focus on emerging technologies.